AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 91 min read$IONS

BENNETT C FRANK sold $463K of IONS

BENNETT C FRANK (EVP, Chief Scientific Officer) sold 5,536 shares of IONIS PHARMACEUTICALS INC (IONS) at $83.58 ($0.46M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BENNETT C FRANK
Published Jul 9, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IONS
Neutral
high confidence
Mentioned
$IONS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

This provides a datapoint on insider activity but does not introduce new company-specific fundamentals or catalysts.

02

Market read

Traders may monitor insider activity, but the 10b5-1 structure and lack of new fundamentals suggest limited trading edge.

03

What to watch

The filing does not include any new clinical, regulatory, or financial guidance; without those, the trading signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed July 9, transaction dated July 7 (10b5-1 sale).

Background

The article is a SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals, reported by an EVP and Chief Scientific Officer.

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals disclosed an EVP Chief Scientific Officer open-market sale of 5,536 shares at $83.5790 on July 7 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; treat as informational rather than a directional signal.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

Minimal read-across to biotech sector fundamentals; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    IONIS PHARMACEUTICALS INC

    Company whose Form 4 insider transaction was filed.

  • insider
    BENNETT C FRANK

    EVP, Chief Scientific Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IONS insider trading history →

Related articles

OCT 16
$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

rttnews.com3 min
OCT 16
$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

tradingview.com2 min
OCT 16
$IONSHigh

CHMP Backs Ionis TRYNGOLZA For Severe Hypertriglyceridemia In Europe

Ionis Pharmaceuticals (IONS) reported that the EMA's CHMP recommended approval of TRYNGOLZA for severe hypertriglyceridemia in Europe. If approved, it would be the first RNA-targeted therapy for this condition. The recommendation is based on Phase 3 studies showing significant reductions in triglycerides and acute pancreatitis events. IONS stock was up 3.33% on Thursday and is up 0.61% in pre-market trading.

rttnews.com1 min
OCT 16
$IONSHigh

Ionis Pharmaceuticals (IONS) Gains CHMP Nod for Tryngolza Expans

Ionis Pharmaceuticals (IONS) received a positive opinion from the CHMP for expanding Tryngolza's use to treat severe hypertriglyceridemia in adults, pending EU Commission approval. The company's P/S ratio is 8.25, below its historical median, and it has a GF Score™ of 63/100, indicating mixed fundamentals. Insiders have been net sellers, and guru investors show cautious sentiment.

gurufocus.com2 min